Finally, purpactin A was found to consistently act as an elastase inhibitor with possible application in the treatment of chronic obstructive pulmonary disease [42] and as an inhibitor of TMEM16A, a Ca2+-activated Cl− channel protein involved in mucus secretion in inflamed airways, which has been proposed as a drug target for diseases associated with mucus hypersecretion, including asthma. This evidence concerns the gene ANO1 and chronic obstructive pulmonary disease.